Ind-Swift Laboratories Ltd Hits New 52-Week High at Rs.139.25

Strong Rally Drives New High

On 9 Feb 2026, Ind-Swift Laboratories Ltd reached an intraday high of Rs.139.25, representing a 5.73% increase on the day. This advance outpaced the Pharmaceuticals & Biotechnology sector by 3.5%, underscoring the stock’s robust upward trajectory. The company’s shares have been on a consistent rise, recording gains over the past five consecutive trading sessions. During this period, the stock delivered a remarkable 27.28% return, a performance that significantly eclipses the Sensex’s 3% gain over the last three weeks.

The stock’s 52-week low stands at Rs.67.15, highlighting the substantial recovery and growth achieved over the past year. In fact, Ind-Swift Laboratories Ltd’s one-year return of 33.53% far exceeds the Sensex’s 7.86% gain, reflecting the company’s relative strength within the market.

Technical Indicators Confirm Uptrend

Technical analysis supports the bullish momentum, with Ind-Swift Laboratories Ltd trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment of moving averages is often interpreted as a strong signal of sustained upward momentum. The stock’s ability to maintain levels above these benchmarks suggests investor confidence in its current valuation and underlying fundamentals.

Meanwhile, the broader market environment remains positive. The Sensex opened higher at 84,177.51, gaining 597.11 points (0.71%) before settling at 83,985.81, still up 0.49%. Although the Sensex is trading below its 50-day moving average, the 50DMA remains above the 200DMA, indicating a generally constructive medium-term trend. Mega-cap stocks continue to lead the market, contributing to the overall positive sentiment.

Mojo Score and Rating Upgrade

Ind-Swift Laboratories Ltd’s recent performance has been reflected in its MarketsMOJO rating. The company’s Mojo Score currently stands at 51.0, categorised as a Hold grade. This represents an upgrade from a previous Sell rating, which was revised on 5 Feb 2026. The improvement in rating aligns with the stock’s upward price movement and enhanced market sentiment.

The company’s market capitalisation grade is rated at 4, indicating a moderate market cap relative to its sector peers. This grading provides additional context for investors analysing the stock’s position within the Pharmaceuticals & Biotechnology industry.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector has experienced mixed trends recently, but Ind-Swift Laboratories Ltd’s outperformance stands out. The stock’s 4.63% gain on the day and its consistent rise over the past week highlight its resilience and ability to capitalise on sector tailwinds. This is particularly notable given the broader market’s cautious stance, with the Sensex still 2.59% below its own 52-week high of 86,159.02.

Ind-Swift Laboratories Ltd’s rally is supported by strong fundamentals and technical momentum, positioning it as one of the more dynamic stocks within its sector. The company’s ability to sustain gains above key moving averages and its recent rating upgrade further reinforce this view.

Summary of Price Performance

To summarise, Ind-Swift Laboratories Ltd’s stock price has demonstrated significant strength over the past year. From a 52-week low of Rs.67.15, the stock has more than doubled to reach Rs.139.25, marking a 33.53% gain over the last 12 months. This performance is well ahead of the Sensex’s 7.86% rise during the same period.

The stock’s recent five-day rally, delivering over 27% returns, highlights a period of accelerated momentum. The day’s 5.73% intraday high increase and outperformance relative to the sector by 3.5% further underscore the stock’s robust price action.

Trading above all major moving averages, the stock’s technical indicators remain firmly positive. The MarketsMOJO upgrade from Sell to Hold on 5 Feb 2026 reflects this improved outlook, supported by a Mojo Score of 51.0 and a market cap grade of 4.

Market Environment and Broader Implications

While the Sensex continues to consolidate below its 52-week high, Ind-Swift Laboratories Ltd’s strong performance within the Pharmaceuticals & Biotechnology sector stands out. The stock’s ability to maintain gains amid a mixed market backdrop highlights its relative strength and the positive reception of its recent developments.

Overall, the new 52-week high of Rs.139.25 represents a key milestone for Ind-Swift Laboratories Ltd, reflecting sustained investor confidence and solid market positioning within its sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →